Author:
Zhu Chuan-cong,Fu Si-yu,Chen Yu-xin,Li Ling,Mao Ruo-lin,Wang Jian-zhi,Liu Rong,Liu Yi,Wang Xiao-chuan
Abstract
SummaryAlzheimer’s disease (AD) is a chronic neurodegenerative disease that mainly causes dementia. It is a serious threat to the health of the global elderly population. Considerable money and effort has been invested in the development of drug therapy for AD worldwide. Many drug therapies are currently under development or in clinical trials, based on two known mechanisms of AD, namely, Aβ toxicity and the abnormal Tau hyperphosphorylation. Numerous drugs are also being developed for other AD associated mechanisms such as neuroinflammation, neurotransmitter imbalance, oxidative damage and mitochondrial dysfunction, neuron loss and degeneration. Even so, the number of drugs that can successfully improve symptoms or delay the progression of the disease remains very limited. However, multi-drug combinations may provide a new avenue for drug therapy for AD. In addition, early diagnosis of AD and timely initiation of treatment may allow drugs that act on the early pathological processes of AD to help improve the symptoms and prevent the progression of the condition.
Publisher
Springer Science and Business Media LLC
Reference77 articles.
1. Wenk GL. Neuropathologic changes in Alzheimer’s disease. J Clin Psychiatry, 2003,64(Suppl 9):7–10
2. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol, 2018,25(1):59–70
3. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med, 2012,366(10): 893–903
4. Hyde C, Peters J, Bond M, et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model. Age Ageing, 2013,42(1): 14–20
5. Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y), 2020,6(1): e12050
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献